Pulmonary Ewing Sarcoma Presenting As Chronic Cough Authors: Pushpapriya Balaji, Irfan Ismail Ayub, Thangaswamy Dhanasekar, Leena Joseph, Lawrence D'Cruze Published: 2026 ABSTRACT Ewing sarcoma is an aggressive malignant small round cell tumour primarily affecting bone and soft tissue in young individuals. Pulmonary involvement is commonly seen in metastatic disease, while late recurrence after a prolonged disease-free interval is uncommon and may pose a diagnostic challenge. We report a 26-year-old male with previously treated non-metastatic Ewing sarcoma of the left fibula, who presented four years later with persistent chronic cough. Imaging revealed a large heterogeneously enhancing mass in the left lower lobe with bronchial cutoff, raising suspicion for primary lung malignancy. However, histopathology demonstrated small round blue cells, and immunohistochemistry confirmed Ewing sarcoma, consistent with late primary recurrence. This case underscores the importance of maintaining a high index of suspicion for recurrence in patients with prior malignancy presenting with non-specific respiratory symptoms. It highlights the potential for atypical presentations and the need for timely imaging and tissue diagnosis to guide appropriate management. Introduction Ewing sarcoma is a malignant small round cell tumour that constitutes approximately 10-15% of all primary bone malignancies, with peak incidence in the second decade of life. It most commonly arises from long bones such as the femur, tibia, and fibula, accounting for nearly 70-80% of cases, while extra-skeletal involvement is less frequent [1]. Despite advances in multimodal therapy, recurrence occurs in nearly 30-40% of patients, with the lung being the most common site of metastasis, seen in 50-60% of relapsed cases. Most recurrences occur within two to three years of treatment; however, late recurrences beyond three years, though less frequent, account for approximately 10-20% of cases and may present with non-specific symptoms [1,2]. While pulmonary involvement in Ewing sarcoma is well recognised in the setting of metastatic disease, isolated pulmonary or late recurrence after a prolonged disease-free interval remains uncommon and diagnostically challenging. Recent literature highlights that primary or extraosseous pulmonary Ewing sarcoma is exceedingly rare, with only a limited number of cases reported worldwide, and is frequently misdiagnosed due to overlapping clinical and histopathological features with more common lung malignancies such as small cell lung carcinoma [3]. Furthermore, thoracic Ewing sarcoma often presents with non-specific respiratory symptoms such as cough, dyspnoea, or chest pain, which may mimic benign respiratory conditions and delay diagnosis. Case reports and recent series have emphasised that such atypical presentations can lead to initial misdiagnosis and delayed appropriate management [2]. Our case is notable for a late pulmonary recurrence presenting solely as chronic cough after a four-year disease-free interval, underscoring the importance of maintaining a high index of suspicion for recurrence in patients with a prior history of Ewing sarcoma, even when presenting with seemingly benign respiratory symptoms. Case presentation A 26-year-old male presented with complaints of cough with scanty mucoid expectoration for three months. Patient had no history of fever, haemoptysis, chest pain, dyspnoea, or significant weight loss. There were no identifiable environmental or occupational risk factors, and the patient had no history of smoking. The patient was diagnosed with Ewing sarcoma of the left fibula, with no distant metastasis, in 2019. He underwent eight cycles of neoadjuvant chemotherapy, subsequently followed by fibulectomy and chemoradiation, completed in 2020. He remained asymptomatic thereafter and was on routine follow-up. On examination, the patient was hemodynamically stable. Respiratory examination revealed decreased breath sounds in the left infrascapular and infra-axillary areas, with no added sounds. Routine laboratory investigations at presentation were within normal limits. The thorax CECT showed a posterior mediastinal mass with mediastinal lymphadenopathy. Whole-body PET-CT scan revealed a fluorodeoxyglucose (FDG)-avid (SUVmax 6.6) heterogeneously enhancing mass measuring 8.0 × 7.3 × 8.7 cm in the left lower lobe with evidence of bronchial cutoff. No other metabolically active lesions were identified elsewhere in the body (Figure 1). FDG-avid (SUVmax 6.6) heterogeneously enhancing mass measuring 8.0 × 7.3 × 8.7 cm in the left lower lobe with bronchial cutoff cm - centimetre; FDG - fluorodeoxyglucose; SUVmax - maximum standardised uptake value CT-guided biopsy of the lung mass showed sheets of uniform small round blue cells with round nuclei and scant cytoplasm (Figure 2). Immunohistochemical analysis revealed strong membranous positivity for CD99, along with nuclear positivity for FLI-1 and NKX2.2 (Figure 3). Based on the clinical history, imaging, and histopathological findings, a diagnosis of late pulmonary recurrence (metachronous metastasis) of Ewing sarcoma was made. Haematoxylin and eosin stain: uniform, small round cells with round nuclei, inconspicuous nucleoli and scant cytoplasm - small round blue cell tumour favouring Ewing sarcoma (A - 100×, B - 40×) Immunohistochemistry showing positive for (A) NKX 2.2 (40×), (B) CD99 (100×), and (C) FLI-1 (40×) Molecular confirmation with EWSR1 rearrangement analysis could not be performed due to resource limitations. The patient was subsequently referred for oncological management; however, he was lost to follow-up after the establishment of the diagnosis, and details regarding further treatment could not be obtained. Discussion Ewing sarcoma is an aggressive malignant small round blue cell tumour with a high propensity for distant metastasis, most commonly involving the lungs. Approximately 70% of recurrences occur within two to three years of initial therapy [1], while late relapse beyond three years is well recognised and accounts for approximately 10-20% of cases, often presenting diagnostic challenges due to non-specific symptoms [2]. In the present case, the patient developed a large lung mass four years after completion of multimodal therapy, following a prolonged asymptomatic period. Clinically, Ewing sarcoma most commonly presents with localised pain (reported in ~60-70% of cases) and swelling, while systemic symptoms, such as fever and weight loss, are less frequent (~20-30%) [4]. Pulmonary involvement may present with non-specific respiratory symptoms such as cough, chest pain, or dyspnoea, and can occasionally remain asymptomatic in early stages [4]. Given the prior history of Ewing sarcoma and the lung being the most frequent site of metastatic spread, this presentation is most consistent with a metachronous pulmonary recurrence [5,6]. Although primary pulmonary Ewing sarcoma remains a differential diagnosis, it is exceedingly rare, accounting for <1% of all cases, and typically requires molecular comparison to distinguish it from metastatic disease [7-9] Imaging modalities such as CECT and PET-CT are essential for assessing lesion characteristics, extent of disease, and identifying additional metastatic sites. PET-CT provides functional information and is useful in staging and response assessment. Definitive diagnosis relies on histopathological examination, which demonstrates sheets of small, round blue cells. However, due to overlapping morphology with other malignancies, immunohistochemistry is indispensable. Markers, such as CD99, are highly sensitive, while NKX2.2 and FLI-1 improve diagnostic specificity [10,11]. Molecular diagnostics play a pivotal role in confirming Ewing sarcoma, particularly in atypical presentations or uncommon sites. Detection of EWSR1 gene rearrangement using fluorescence in situ hybridisation (FISH) or reverse transcription polymerase chain reaction (RT-PCR) is considered the gold standard and helps differentiate Ewing sarcoma from other small round blue cell tumours [12]. However, in resource-limited settings, diagnosis is often based on characteristic histomorphology and supportive immunohistochemistry, especially diffuse membranous CD99 positivity, as seen in our case. Surveillance following treatment of Ewing sarcoma is critical, as recurrence occurs in approximately 30-40% of patients, most commonly within the first two to three years. Current recommendations suggest regular clinical evaluation and imaging, including chest CT, given that the lung is the most frequent site of metastasis. However, late recurrences beyond three years, although less common, are well documented and may present with non-specific symptoms, posing a diagnostic challenge. A review of recent literature indicates that pulmonary presentations of Ewing sarcoma, whether primary or metastatic, are rare and often mimic primary lung malignancies or benign respiratory conditions. Most reported cases present with symptoms such as chest pain, dyspnoea, or hemoptysis, and only a limited number describe isolated chronic cough as the presenting complaint. Furthermore, reports of late pulmonary recurrence after a prolonged disease-free interval remain limited. In this context, our case is noteworthy for presenting as an isolated chronic cough due to late pulmonary recurrence after four years, without other systemic features. This highlights the potential for atypical and misleading clinical presentations and underscores the importance of maintaining a high index of suspicion in patients with prior malignancy, even when symptoms appear benign. Management of recurrent Ewing sarcoma is complex and requires a multidisciplinary approach. Systemic chemotherapy remains the mainstay, with multi-agent regimens commonly employed [5]. In selected patients with isolated pulmonary metastasis, local therapies, such as metastasectomy or radiotherapy, may improve outcomes [1,5]. Prognosis remains guarded, with better survival observed in patients with isolated lung involvement compared to those with extrapulmonary disease [6]. This report is limited by its single-case design, absence of follow-up and treatment data, and lack of molecular confirmation, which may affect generalizability. Further studies are needed to better characterise such atypical presentations. Conclusions Ewing sarcoma may recur after prolonged disease-free intervals, and such late recurrences can present with subtle, non-specific symptoms that easily mimic benign conditions. Persistent respiratory symptoms, including isolated chronic cough, should therefore not be overlooked in patients with a prior history of malignancy. This case underscores the need to avoid anchoring bias and highlights the importance of maintaining clinical vigilance, particularly as the lung remains a common site of relapse irrespective of the primary tumour location. Early imaging and tissue diagnosis are essential for the timely identification of recurrence, which may broaden therapeutic options. These findings reinforce the critical role of structured follow-up and primary care physicians in recognising atypical presentations and facilitating prompt specialist referral.